Objective: The aim of this study is to assess the association between epicardial adipose tissue (EAT) and coronary artery disease (CAD) via meta−analysis. Methods: Specific searches of online databases from January 2000 to May 2022 were conducted. All observational studies evaluating the association between EAT and CAD in PubMed, Web of Science, and the Cochrane Library databases were screened. A meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta−Analyses guidelines (PRISMA). In total, 21 studies encompassing 4975 subjects met the inclusion criteria, including 2377 diagnosed and assigned as the CAD group, while the other 2598 were assigned as the non−CAD group. Subjects in the CAD group were further divided into the severe stenosis group (stenosis ≥ 50%, n = 846) and the mild/moderate stenosis group (stenosis < 50%, n = 577). Results: Both the volume and thickness of EAT in the CAD group were larger compared to the non−CAD group (p < 0.00001). In a subgroup analysis within the CAD group, the severe stenosis group had a larger volume and thickness with respect to EAT when compared to the mild/moderate group (p < 0.001). Conclusions: The enlargement of EAT presented in CAD patients with an association with CAD severity. Although limited by different CAD types and measuring methods for EAT, as well as a smaller sample size, our results suggest that EAT is a novel predictor and a potential therapeutic target for CAD.
Although heart transplantation remains the definitive therapy for end-stage heart failure, its widespread application is constrained by conventional static cold storage (SCS), where prolonged cold ischemia inflicts irreversible injury. Current preservation solutions lack pharmacologically active components capable of targeting unique hypothermia-induced damage, including lipid phase separation, mitochondrial decay, and restricted succinate clearance, which collectively trigger a devastating oxidative stress burst upon reperfusion. To address this clinical bottleneck, this review systematically deciphers the pathophysiology of cold ischemic injury, framing the discussion around the metabolic distinctions between warm and cold ischemia. We synthesize pivotal molecular interventions targeting oxidative stress cascades, programmed cell death networks (such as apoptosis and ferroptosis), sterile inflammation, organelle impairment, and epigenetic dysregulation, while clarifying their specific applicable scenarios. Crucially, we evaluate the therapeutic superiority of natural products derived from plants, fungi, and marine animals as multi-target synergistic agents, while confronting translational barriers involving their low bioavailability and complex regulatory approval. Ultimately, we outline actionable paradigms to bridge this translational gap, highlighting nanocarrier-based advanced drug delivery and the utilization of in vitro mechanical perfusion as an active therapeutic platform. Integrating these tools with multi-omics profiling allows for personalized, donor-specific preservation strategies. Together, this comprehensive review provides essential theoretical insight and practical guidance to optimize donor graft viability and advance the field of myocardial protection worldwide.